ClinicalTrials.gg
RecruitingNCT06025149UnilineUpdated Sep 25, 2024

The Study on the Use of "UniLine" Bioprosthesis in the Treatment of Isolated Aortic and Mitral Valve Diseases

An observational study in Aortic Valve Disease and Mitral Valve Disease, sponsored by Closed Joint-Stock Company NeoCor. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Closed Joint-Stock Company NeoCor · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2018; still recruiting 8 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this open, prospective, multicenter study is analyze long-term outcomes of aortic/mitral valve replacement using the "UniLine" bioprosthesis in patients with acquired aortic or mitral valve diseases.

Main research objectives:

To analyze long-term (up to 12 years) outcome of aortic or mitral valve replacement using the "UniLine" bioprosthesis.

To study the hemodynamic characteristics of normally functioning "UniLine " prostheses in the mitral or aortic valve position based on the transthoracic echocardiography data.

To assess the number, type, time frames of dysfunctions of UniLine bioprostheses and the results of their treatment.

To analyze the frequency of major serious adverse events associated with the "UniLine" bioprosthesis or procedure.

Read the detailed description

Acquired heart diseases (AHDs) remain one of the most frequent causes of cardiac mortality and disability. In Russia, this kind of disease accounts for 7 to 25 % of all cardiovascular diseases, and is third most common cause of heart failure.

Heart valve replacement using a prosthetic heart valve remains the main and most effective method of treatment of AHDs. In Russia, AHDs are treated in more than 40 subjects by specialists from 92 medical institutions. Valve replacements, being high-tech methods of treatment, most effectively prolong the life of patients. Timely correction of AHD allows 75-95 % of patients to return to a normal lifestyle.

The aim of this study is to evaluate the safety and effectiveness of the "UniLine" epoxy-treated bioprosthesis in the treatment of isolated mitral or aortic heart valve diseases.

The expected clinical benefit involves the treatment of valvular disease with restoration of intracardiac hemodynamics during implantation of the "UniLine " bioprosthetic valve, followed by remodeling of the heart chambers, which should lead to an improvement in heart function and quality of life of the patient.

The expected risks are associated with taking anticoagulant therapy during the first three months after implantation, or as a result of prolonged anticoagulant therapy, in the presence of concomitant rhythm disturbances, and consist in the possibility of hemorrhagic or thromboembolic complications.

02

Conditions studied

  • Aortic Valve Disease
  • Mitral Valve Disease

Browse trials for

Keywords

  • UniLine biological prosthesis
  • Acquired valve disease
  • Acquired aortic valve disease
  • Acquired mitral valve disease
03

In context

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

This study's planned enrollment of 300 is above the median of 200 across 107 observational studies indexed under Aortic Valve Disease.

Browse Aortic Valve Disease studies →

Lead sponsor

Closed Joint-Stock Company NeoCor is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

As part of these clinical trials (studies), the use of comparison groups is not planned.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provided to participate in the study.
  2. Must be aged 18 years and older.
  3. Patients with isolated acquired mitral or aortic valve disease.
  4. No prior heart valve replacement, current replacement must be planned (not conducted in an urgent/ emergency manner), using the "UniLine" biological prosthesis made from xenopericardium.
  5. Patient must be able to visit the Research Center.

Exclusion criteria

Exclusion Criteria:

  1. Mechanical or biological prosthesis in another position. Patients with tricuspid valve repair may be included in the study.
  2. Prior heart valve replacement.
  3. Concomitant interventions on the heart (coronary artery bypass grafting, coronary heart disease treatment, surgical reconstruction of a left ventricular aneurysm) and thoracic aorta.
  4. Patients with cancer in history.
  5. Patients with musculoskeletal conditions with severe movement disorders and diseases of the central nervous system, accompanied by cognitive disorders (disorientation, inability to independently reach the destination).
  6. Acute or subacute stages of infective endocarditis.
  7. Class IV heart failure according to the Functional Classification with ongoing therapy, less than 40%, myocardial infarction less than 90 days old, angina pectoris grade 4.
  8. The presence of severe somatic, neurological, mental and infectious diseases that worsen the prognosis of long-term survival: tuberculosis, , Alzheimer's disease, epilepsy, chronic kidney disease stage 3b ( less than 30 mL/ min / 1.73 m²), chronic lung diseases requiring constant intake of and bronchodilators, multifocal atherosclerosis (grade 3 chronic lower limb ischemia, stenosis of the carotid arteries more than 50%, prior and planned interventions on the abdominal aorta, carotid arteries or arteries of the lower extremities).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Safety of the Bioprosthetic Valve

    Safety of using the bioprosthesis is defined as the absence of major adverse events related to the device or procedure, assessed using the following clinical phenomena: 1. Fatal outcome: a) all-cause death; b) related to cardiovascular diseases; c) related to the dysfunction of the prosthesis. 2. Life-threatening bleeding. 3. Any dysfunction associated with the bioprosthesis (stenosis, regurgitation), migration of the device, thrombosis or other complication requiring surgical intervention. 4. Any dysfunction associated with the bioprosthesis that does not require surgical intervention. 5. Myocardial infarction (or stroke) or progression of a chronic form of ischemia requiring percutaneous coronary intervention or coronary artery bypass graft surgery 6. Stroke

    Time frame: 12 years since the replacement surgery

  2. Long-Term Durability of the Bioprosthetic Valve

    It will be evaluated by measuring the hemodynamic characteristics of the prosthetic valve, assessed by echocardiography: maximum, average gradients and effective orifice area (absolute and indexed values).

    Time frame: 12 years since the replacement surgery

Secondary outcomes

  1. Hemodynamic characteristics of the Bioprosthetic Valve

    They will be assessed by using echocardiography: maximum, average gradients and effective orifice area (absolute and indexed values).

    Time frame: 12 years since the replacement surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Sep 2025, 84 months after the start.

Of 47 non-industry observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 147. This study's planned 84 months is above that.

Counting every sponsor, half of 56 studies reached it within 49 months; a quarter within 23 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 6, 2023
StartActual
Sep 1, 2018
Primary completionEst.
Sep 9, 2025
CompletionEst.
Jan 31, 2035
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06025149
Lead sponsor
Closed Joint-Stock Company NeoCor
Collaborators
Research Institute for Complex Problems of Cardiovascular Diseases, Russia, CT Medical Limited Liability Company
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Sep 1, 2018
Primary completion
Sep 9, 2025 (estimated)
Completion
Jan 31, 2035 (estimated)
Last update
Sep 25, 2024

Study contacts

Evgeny Bazdyrev, MD, PhD
Contact
clinicresearch@kemcardio.ru
+7-3842-64-42-40
Michael Karelin
Contact
karelin@ctmedical.ru
8 (913) 433 7669
Alexander Bogachev-Prokofiev, MD, PhD
principal investigator · National Medical Research Center named after Academician E.N. Meshalkin
Alexey Evtushenko, MD, PhD
principal investigator · Research Institute for Complex Issues of Cardiovascular Diseases

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion